![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Lays Out New Guidance on Cancer Endpoints
FDA Lays Out New Guidance on Cancer Endpoints
December 27, 2018
Cancer trials that rely on event-free survival and complete response to treatment as surrogate endpoints will be acceptable to FDA reviewers, the agency said in a new final guidance.
The FDA also is willing to consider emerging endpoints such as symptom improvement or relief, minimal residual disease or metastasis-free survival, the 19-page document states.
The guidance replaces a 2007 document to provide updated thinking on an industry that has evolved rapidly in the past decade or more, the agency said.
Upcoming Events
-
21Oct